(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges

BMC Cancer
Tatiana C SchneiderHans Morreau

Abstract

Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side effect of sorafenib is the occurrence of cutaneous squamous tumors. Here we describe three patients with a history of sorafenib treatment for advanced radioactive iodine refractory papillary thyroid cancer (two with a BRAF c.1799 T > A and one carrying a rare c.1799-1801het_delTGA mutation) who presented with secondary non-cutaneous lesions. The first patient was diagnosed with a squamous cell carcinoma (SCC) of the tongue, the second patient with a primary adenocarcinoma of the lung, and the third with a SCC originating from the cricoid. Secondary analysis was required to show that the latter two presentations were in fact recurrent thyroid cancer. These findings suggest that drugs such as sorafenib may induce metaplasia/clonal divergence of metastatic thyroid cancer and thus cause diagnostic misclassification. Furthermore, sorafenib is potentially involved in the tumorigenesis of secondary non-cutaneous SCC. These observati...Continue Reading

References

Jun 19, 2008·Archives of Dermatology·David S HongRazelle Kurzrock
Feb 14, 2009·Clinical Genitourinary Cancer·Zita DubauskasNizar M Tannir
Aug 8, 2009·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Kathleen J SmithHenry G Skelton
Dec 5, 2009·The Journal of Molecular Diagnostics : JMD·Ronald van EijkTom van Wezel
Mar 19, 2011·International Journal of Dermatology·Victoria L WilliamsDavid J Stewart
Nov 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean Philippe ArnaultCaroline Robert
Jan 20, 2012·The New England Journal of Medicine·Fei SuRichard Marais
Nov 9, 2012·The New England Journal of Medicine·Margaret K CallahanPaul B Chapman
Nov 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Miles C AndrewsJonathan Cebon

❮ Previous
Next ❯

Citations

Aug 23, 2016·Nature Cell Biology·Julia FredePhilip H Jones
Jun 9, 2020·Oxidative Medicine and Cellular Longevity·Abdullah F AlAsmariAli A Alshamrani

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
PCR
Assay
dissection
biopsy

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Rossella EliseiSteven I Sherman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Vandana Gupta-AbramsonMarcia S Brose
© 2022 Meta ULC. All rights reserved